The Company announces that pursuant to the exclusive licence and distributor agreement with Thermo Scientific, a cumulative sales milestone has been achieved by Thermo Scientific. Pursuant to the sales milestone, a milestone payment of £0.87m has been received by the Company and will be recognised in the 2022 financial year.++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Proteome Sciences announces that further to the announcement of Abdelghani Omari’s appointment as Chief Financial Officer on 18 August 2022 (the “Appointment Announcement”), Mr Omari has today been granted 4,000,000 options by the Company under the Company's share option scheme ("Options"). The Options are to be issued at nominal value and will vest in three equal annual tranches on 1 September 2023, 1 September 2024 and 1 September 2025. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary.
Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company (“Ordinary Shares”) under the Company’s share option schemes (“Options”). A total of 3,000,000 Options were yesterday issued to two directors of the Company.
Proteome Sciences Plc ("Proteome Sciences", or "the Company") announces that the Board has approved the appointment of Cooper Parry Group Limited (Cooper Parry) as the Group's new external auditor, and that BDO LLP ("BDO") has resigned as the Group's auditor.
The Board of Proteome Sciences plc is pleased to announce that Abdelghani Omari has been appointed as the Company’s new Chief Financial Officer. He will take up the position on September 1st, 2022 and will become a director of the Company.
Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to Interim Results via the Investor Meet Company platform on 18th August 2022 at 10:30am BST.
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2022.
Proteome Sciences is pleased to announce that the Company has completed the next milestone towards the launch of Single Cell Proteomics services, which will be known as SysQuant® SCP, with the installation of a cellenONE® (Cellenion, France) platform that allows the semi-automated preparation of up to 2,700 cells per week.